Evonik Shares Receive Multiple Catalysts Simultaneously

Barclays upgrades Evonik to 'Overweight' citing a 10% methionine price hike, strategic divestments, and the launch of a PFAS-free anti-graffiti solution for new regulations.

A confluence of positive developments is emerging for Evonik, a chemical stock that has shed approximately 35% of its value over the past year. These include a significant analyst upgrade, rising prices for a key product, and the launch of a new offering designed for a tightening regulatory environment.

Barclays Upgrades on Methionine Dynamics

In a notable shift, analysts at Barclays have raised their rating on Evonik from 'Equal Weight' to 'Overweight'. Their price target was also increased from €16 to €17 per share. The reassessment is primarily driven by shifting conditions in the methionine market. This feed additive is a major product for Evonik.

Supply chain disruptions stemming from the Middle East conflict have tightened the flow of raw materials via the Strait of Hormuz, putting pressure on Chinese competitors as well. Furthermore, Evonik itself declared force majeure for a supplier, leading to partial production constraints at its Singapore methionine plant. Barclays notes, however, that only a minor segment of the facility is affected.

Critically, Evonik has already announced an immediate net price increase of 10% for its MetAMINO® product across all markets. In response to these developments, Barclays revised its net price assumption from negative €105 million to zero. The bank subsequently lifted its 2026 EBITDA estimate to €1.89 billion. This figure sits 3% above the Bloomberg consensus but remains within the company's own guidance range of €1.7 to €2.0 billion.

Strategic Divestments and a PFAS-Free Innovation

Barclays also highlighted the potential value from Evonik's planned portfolio divestments. During its recent Capital Markets Day, management outlined a strategy to forgo acquisitions until 2027, focusing instead on debt reduction and the sale of certain business units—specifically Syneqt and Oxeno. Syneqt alone generates annual EBITDA of around €200 million. The analysts suggest a sale could potentially command a higher valuation multiple than Evonik's current conglomerate level.

On the innovation front, Evonik is launching Protectosil ECO-TRETE® ANTIGRAFFITI, a product with regulatory significance. This new anti-graffiti solution is formulated without added PFAS chemicals, instead relying on silane chemistry. It directly addresses increasingly stringent environmental regulations in the construction protection sector. The product will make its public debut at the EUROCOAT exhibition in Paris from March 24th to 26th.

Solid Financial Foundation Amid Technical Weakness

The company's full-year 2025 results provide a fundamental backdrop. Adjusted EBITDA came in at €1.87 billion, aligning with its own forecast. Free cash flow reached €695 million, resulting in a cash conversion rate of 37%—the upper end of the target range. Revenue, however, declined by 7% to €14.1 billion.

Despite the positive news flow, Evonik's share price currently trades at €13.91, notably below its 200-day moving average of €14.93. The market will soon test whether the combination of the analyst upgrade, methionine price increases, and impending asset sales provides enough momentum to sustainably overcome this technical resistance. This will become clearer once second-quarter pricing trends for methionine are fully reflected in valuations.